At the time of writing, Sangamo Therapeutics Inc [SGMO] stock is trading at $1.50, up 0.67%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SGMO shares have gain 62.92% over the last week, with a monthly amount glided 77.62%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sangamo Therapeutics Inc [NASDAQ: SGMO] stock has seen the most recent analyst activity on November 03, 2023, when RBC Capital Mkts downgraded its rating to a Sector Perform and also revised its price target to $2 from $6. Previously, BofA Securities downgraded its rating to Underperform on April 28, 2023, and dropped its price target to $1.50. On February 27, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $16 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $5 on January 06, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on May 04, 2021, and assigned it a price target of $22.
For the past year, the stock price of Sangamo Therapeutics Inc fluctuated between $0.29 and $1.77. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Sangamo Therapeutics Inc [NASDAQ: SGMO] shares were valued at $1.50 at the most recent close of the market. An investor can expect a potential return of 700.0% based on the average SGMO price forecast.
Analyzing the SGMO fundamentals
According to Sangamo Therapeutics Inc [NASDAQ:SGMO], the company’s sales were 12.28M for trailing twelve months, which represents an -94.79% plunge. Gross Profit Margin for this corporation currently stands at -0.43% with Operating Profit Margin at -20.22%, Pretax Profit Margin comes in at -20.24%, and Net Profit Margin reading is -20.34%. To continue investigating profitability, this company’s Return on Assets is posted at -2.68, Equity is -3.35 and Total Capital is -4.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2800 points at the first support level, and at 1.0600 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7500, and for the 2nd resistance point, it is at 2.0000.
Ratios To Look Out For
It is important to note that Sangamo Therapeutics Inc [NASDAQ:SGMO] has a current ratio of 1.03. As well, the Quick Ratio is 1.03, while the Cash Ratio is 0.71. Considering the valuation of this stock, the price to sales ratio is 25.43, the price to book ratio is 13.18.
